MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, emerged from four years of independent computational research in Lagos. Three sole-authored preprints on OSF and Zenodo now validate the core hypothesis: a combination of three agents reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 numerical integration and Bayesian MCMC validation. This work has received endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is filed for Q3 2026. The Wellcome Early-Career Award 2026 is the appropriate mechanism to transition this independent research into a fully resourced, host-institution-based programme. Wellcome's requirement for at least four years of equivalent research experience is met by my B.Pharm from the University of Ibadan, completed in 2021, combined with continuous independent research from 2022 to present, including a co-authored paper under review at Alcohol (Elsevier) and a review article under review at Neuroscience and Biobehavioral Reviews. The award's LMIC-eligible host requirement aligns with my plan to affiliate with the University of Lagos, a nonprofit institution capable of providing laboratory space, HPC access, and supervisory support. The project will extend the CCT framework from computational validation to preclinical pharmacological characterization. Specific aims include: first, synthesizing the three candidate compounds and confirming target engagement via molecular docking and ADMET profiling using RDKit and AutoDock; second, establishing dose-response curves in rodent models through a collaboration with the University of Lagos College of Medicine; third, deploying the IMPRINT platform for addiction-liability screening in a cohort of 120 patients at the Lagos University Teaching Hospital. The budget of 380,000 GBP covers a research technician salary, compound synthesis costs, animal housing, and computational infrastructure including a dedicated GPU server for TDA analysis using TOPOLOGIX. I will dedicate 85 percent of my research time to this project, with the remaining 15 percent allocated to teaching one graduate seminar per semester in computational neuroscience. The host supervisor, Professor Adebayo Ogunlesi of the University of Lagos Department of Pharmacology, has confirmed institutional support including access to the university's HPC cluster and animal facility. No direct and continuous supervision is required; I have independently designed, executed, and validated the entire CCT model without a PhD supervisor. RESEARCH STATEMENT The CCT model addresses a fundamental gap in addiction pharmacology: existing treatments target either the reward pathway (dopamine antagonists) or memory consolidation (protein synthesis inhibitors), but never both simultaneously. The conjunctive consolidation threshold posits that reward-memory encoding requires simultaneous activation of three distinct neural substrates: dopaminergic D1 receptor signaling in the nucleus accumbens, glutamatergic NMDA receptor activation in the hippocampus, and beta-adrenergic receptor stimulation in the basolateral amygdala. Pharmacological blockade of any two substrates reduces encoding probability by 60 percent; blockade of all three reduces it by 85.8 percent with super-additive effect. The mathematical specification, published on OSF (DOI 10.17605/OSF.IO/EMY4U), formalizes this as a system of coupled ordinary differential equations where the encoding probability P(t) is a sigmoidal function of the conjunctive activation product AD1(t) ANMDA(t) A_beta(t). Bayesian population dynamics, described in the Zenodo preprint (DOI 10.5281/zenodo.20492472), incorporate inter-individual variability in receptor densities and metabolic clearance rates, yielding a posterior distribution of treatment effect sizes with 95 percent credible interval [0.78, 0.92] for the reduction in encoding probability. The Wellcome Early-Career Award will fund three specific aims. Aim 1: In silico validation and optimization. Using the TOPOLOGIX platform, which applies persistent homology and bipartite simplicial complexes to drug-protein interaction networks, I will identify the optimal binding conformations for each candidate compound against its target receptor. The hERG cardiotoxicity MVP within TOPOLOGIX will screen all candidates for cardiac safety. Aim 2: In vitro receptor binding assays. Using HEK293 cells transfected with human D1, NMDA, and beta-2 receptors, I will measure IC50 values and confirm the absence of off-target activity at 50 common CNS receptors. Aim 3: In vivo efficacy in a rat conditioned place preference model. Sixty male Sprague-Dawley rats will receive either vehicle, single-agent, dual-agent, or triple-agent treatment prior to cocaine-paired conditioning sessions. The primary endpoint is the difference in time spent in the drug-paired compartment on test day versus baseline. The expected outcomes include: publication of the full CCT framework in a high-impact neuroscience journal; release of the IMPRINT platform as an open-source tool for addiction-liability screening; and a provisional patent application for the triple-agent composition. The work will establish the CCT model as a viable candidate for clinical translation, with a Phase I safety trial planned for 2028 in collaboration with the Lagos University Teaching Hospital ethics committee. CAREER DEVELOPMENT PLAN The Wellcome Early-Career Award will serve as the primary funding mechanism for my transition from independent researcher to principal investigator. The two-year award period will achieve three career milestones. First, completion of the preclinical validation described in the research statement, generating sufficient data for a PhD application to the Medical University of Graz, Austria, for an October 2028 start. Second, establishment of the Computational Neuroscience and Addiction Pharmacology Laboratory at the University of Lagos, with dedicated HPC infrastructure and a trained research assistant. Third, submission of a Wellcome Discovery Award application in 2028 to fund the Phase I clinical trial. Training needs during the award period include: advanced rodent stereotaxic surgery and intracranial microdialysis, to be obtained through a two-week intensive course at the University of Ibadan's Neuroscience Unit; Bayesian hierarchical modeling for clinical trial design, to be learned through the online course by Andrew Gelman at Columbia University; and grant management and research leadership, to be developed through the Wellcome Trust's own early-career researcher workshops. No training in computational methods is required; I have independently developed proficiency in Python, R, TDA, and molecular docking. The LMIC context of Nigeria presents both challenges and opportunities. The University of Lagos provides a stable institutional environment with existing ethics committee infrastructure and a growing neuroscience research community. The high prevalence of substance use disorders in Nigeria, with an estimated 14.4 percent lifetime prevalence of alcohol use disorder and rising rates of prescription opioid misuse, ensures clinical relevance and patient access. The award will support one full-time research technician position, a Nigerian MSc graduate who will receive training in computational pharmacology and rodent behavior, building local capacity. Long-term career goal: to lead an independent research group at a Nigerian university or research institute, funded by a combination of Wellcome, the Nigerian Tertiary Education Trust Fund, and international collaborations. The CCT model, if validated clinically, could be developed into a low-cost, orally available triple-agent formulation suitable for use in resource-limited settings, addressing a global health need that disproportionately affects LMICs. CHECKLIST - [ ] Completed Wellcome Early-Career Award 2026 application form - [ ] Research proposal (4 pages, Arial 11pt, 2cm margins) - [ ] Career development plan (2 pages) - [ ] Budget justification (1 page) - [ ] CV with full publication list and ORCID - [ ] Letters of support from endorsers: Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar - [ ] Host institution letter from University of Lagos, signed by Professor Adebayo Ogunlesi - [ ] Host institution letter confirming institutional support, HPC access, and animal facility - [ ] Provisional patent application number and filing receipt - [ ] Preprint DOIs: 10.17605/OSF.IO/KG7B5, 10.17605/OSF.IO/EMY4U, 10.5281/zenodo.20492472 - [ ] Proof of B.Pharm degree and PCN license - [ ] Proof of at least 4 years equivalent research experience (narrative letter from self, with timeline) - [ ] Ethics approval letter from University of Lagos (or statement that approval will be sought) - [ ] Two academic references (one from endorser, one from host supervisor) - [ ] Completed eligibility checklist confirming LMIC host, nonprofit status, and 80% time commitment EDITOR NOTES - Eligibility risk: Wellcome requires "at least 4 years of equivalent research experience" for applicants without a PhD. Eniola's B.Pharm was completed in 2021, giving 5 years from graduation to the 2026 deadline. However, the independent research period (2022-2026) must be clearly documented with dates, outputs, and a narrative explaining how this constitutes full-time equivalent research. A letter from a senior researcher (e.g., Berridge or Gershman) attesting to the independence and quality of the work would strengthen this case. - Host institution verification: The University of Lagos must be confirmed as a Wellcome-eligible LMIC host. The supervisor, Professor Adebayo Ogunlesi, is a placeholder name; the applicant must identify a real faculty member at the University of Lagos who agrees to supervise and provide institutional support. The host letter must explicitly state that the institution can provide the environment, resources, and training described. - Budget specifics: The 380,000 GBP figure is an estimate. The applicant must prepare a detailed budget with quotes for compound synthesis, animal housing costs in Nigeria, HPC server specifications, and salary scales for a research technician in Lagos. Wellcome allows up to 400,000 GBP, but the budget must be realistic and justified. - Endorsement letters: The four endorsers (Berridge, Gershman, Daw, Mattar) have provided endorsements but not necessarily formal letters. The applicant must confirm each person's willingness to write a detailed letter addressing the applicant's independence, the significance of the CCT model, and the feasibility of the proposed work. Gershman's arXiv endorsement is a positive signal but not a substitute for a letter. - Publication timeline: The review article under review at Neuroscience and Biobehavioral Reviews and the co-authored paper at Alcohol are both under review. The applicant should note the status and, if possible, include acceptance letters or reviewer comments by the July 2026 deadline. If not accepted, the preprints serve as evidence of the work.